| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 688266 from our risk checks.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥55.30 |
| 52 Week High | CN¥60.11 |
| 52 Week Low | CN¥33.20 |
| Beta | 0.55 |
| 1 Month Change | 5.78% |
| 3 Month Change | 25.54% |
| 1 Year Change | 6.82% |
| 3 Year Change | -16.21% |
| 5 Year Change | n/a |
| Change since IPO | -25.86% |
Recent News & Updates
What Does The Future Hold For Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266)? These Analysts Have Been Cutting Their Estimates
May 08
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Shares Climb 28% But Its Business Is Yet to Catch Up
Mar 06Shareholder Returns
| 688266 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 0.4% | 5.2% | 2.2% |
| 1Y | 6.8% | -12.9% | -10.2% |
Return vs Industry: 688266 exceeded the CN Biotechs industry which returned -12.9% over the past year.
Return vs Market: 688266 exceeded the CN Market which returned -10.2% over the past year.
Price Volatility
| 688266 volatility | |
|---|---|
| 688266 Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in CN Market | 11.0% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 688266's share price has been volatile over the past 3 months.
Volatility Over Time: 688266's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 867 | Zelin Sheng | www.zelgen.com |
Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Fundamentals Summary
| 688266 fundamental statistics | |
|---|---|
| Market cap | CN¥14.66b |
| Earnings (TTM) | -CN¥260.85m |
| Revenue (TTM) | CN¥386.57m |
37.9x
P/S Ratio-56.1x
P/E RatioIs 688266 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688266 income statement (TTM) | |
|---|---|
| Revenue | CN¥386.57m |
| Cost of Revenue | CN¥31.09m |
| Gross Profit | CN¥355.49m |
| Other Expenses | CN¥616.34m |
| Earnings | -CN¥260.85m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 91.96% |
| Net Profit Margin | -67.48% |
| Debt/Equity Ratio | 60.4% |
How did 688266 perform over the long term?
See historical performance and comparison